Haemostatic Effects of Supraphysiological Levels of Testosterone in Normal Men

Summary

The effects of exogenous testosterone on the haemostatic system were studied in a group of 32 healthy men undergoing a clinical trial of hormonal male contraception. The men received 200 mg testosterone oenanthate (TE) weekly i.m., and plasma samples were taken pretreatment, at defined time points up to 52 weeks of treatment, and 4 and 8 weeks after discontinuing TE. This dose of TE caused a 2-fold increase in trough plasma testosterone levels.

TE caused a fall in plasma fibrinogen concentration after 16 weeks of treatment. This was sustained for the duration of TE treatment and recovered to pretreatment levels during the recovery phase. There was also a sustained fall in the level of C4b binding protein which showed a rebound to levels above pretreatment during recovery. Levels of antithrombin III and prothrombin fragment F1.2 rose initially during TE treatment, and levels of protein C, protein S (free) and plasminogen activator inhibitor fell, but the concentrations of these factors all returned to pretreatment levels during continued treatment. There was no change in the plasma concentrations of β-thromboglobulin, tissue plasminogen activator, protein S (total), or D-dimer. There was a sustained increase in haemoglobin concentration and haematocrit, without any change in platelet count.

The observed changes were consistent with mild activation of the haemostatic system during initial treatment with testosterone. After several months the raised activation markers had returned to pretreatment levels indicating that a new equilibrium had been established which did not appear to be prothrombotic. The increase in prothrombin fragment F1.2 for the first 32 weeks, and at four weeks after discontinuation of treatment, is consistent with prolonged mildly increased prothrombinase activity. The observed substantial fall in fibrinogen is likely to have reduced, whereas the small rise in haemoglobin will have increased, the tendency to arterial thrombosis. We conclude that supraphysiological doses of testosterone do not result in a sustained marked prothrombotic state, but these results do not exclude a small change in thrombotic risk.

• References

• 1 World Health Organisation Task Force for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men Lancet 1990; 336: 955-959
• 2 Lowe GDO, Thomson JE, Reavey MM, Forbes CD, Prentice CR M. Mesterolone: thrombosis during treatment, and a studyof its prothrombotic effects. Br J Clin Pharmacol 1979; 7: 107-109
• 3 Ferenchick GS. Are androgenic steroids thrombogenic. N Engl J Med 1990; 322: 47
• 4 Robinson RJ, While S. Misuse of anabolic drugs. Br Med J 1993; 306: 61
• 5 Uzunova A, Ramey E, RamweH PW. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature 1075; 261: 712-713
• 6 Klufi C, Preston PE, Malia RG, Beilina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijcwaard G. Stanozolol-indueed changes in lihrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51: 157-164
• 7 Greer IA, Greaves M, Madhok R, MeLoughlin K, Porter N, Lowe GD O, Preston FE, Forhes CD. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia. Thromb llaemost 1985; 53: 386-389
• 8 Mirand EA, Gordon AW, Wenig J. Mechanism of testosterone action in crythropoiesis. Nature 1065; 206: 270
• 9 Vessey MP, Doll R. Investigation of relation between use of oral contraceptive and thromboembolic disease. Br Med J 1968; 2: 199-205
• 10 Lidegaard O. Oral contraceptives and risk of a cerebral thromboembolic attack: results of a ease-controlled study. Br Med J 1993; 306: 956-963
• 11 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 12 Corker CS, Davidson DW. A radioimmunoassay for testosterone in various biological fluids without chromatography. J Steroid Biochem 1978; 9: 373-374
• 13 Anderson RA, Wu FC W. Pharmacodynamics and pharmacokinetics of testosterone-induced suppression of spermatogenesis: comparison between azoospermic and oligozoospermie responders. 7th Luropean Workshop on Molecular and Cellular Endocrinology of the Testis 1992; 39
• 14 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RA, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 1986; 2: 533-537
• 15 Ernst FibrinogenE. An independent risk factor for cardiovascular disease. Br Med J 1991; 303: 596-597
• 16 Koenig W, Sund M, Lowe GD O, Lee AJ, Reseb KL, Tunslall-Pedoe H, Keil U, Emst L. Geographical variations in plasma viscosity and relation to coronary artery event rates. Lancet 1994; 344: 711-4
• 17 Anderson RA, Wallace EM, Wu FC W. Effect of testosterone oenanthatc on serum lipoproteins in man. Contraception. 1995 in press
• 18 Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Liulocr Revs 1990; 11: 80-91
• 19 Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Anlilhrombin III and arterial disease. Lancet 1991; 338: 850-851
• 20 Carr ME, Zckert SL. Protein S and C4b-binding protein levels in patients with stroke: implications for protein S regulation. Haemostasis 1993; 23: 159-167
• 21 Walker PJ. Identification of a new protein involved in the regulation of the anticoagulant activity of activated protein C, protein S binding protein. J Biol Chem 1986; 261: 941-944
• 22 Glueck CJ, Glueck HI, Stroop D, Hamer T, Tracey T. Endogenous testosterone, fibrinolysis, and coronary heart disease in hyperlipidaemic men. J Lab Clin Med 1993; 122: 412-420
• 23 Kennedy BJ, Gilbertson AS. Increased crythropoiesis induced by androgcnic-hormonc therapy. N Engl J Med 1957; 256: 719
• 24 Francis GL, Berncy JJ, Bateman SM, Hoffbrand AV. The effect of androstancs on granulopoiesis in vitro and in vivo. Br J Haematol 1977; 36: 501-510
• 25 Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection. Med Hypotheses 1991; 35: 27-31
• 26 Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, Guillcbaud J, Machin SJ. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. Br Med J 1991 302: 269-271